Overview
Commercially, PDA exists because BPC-157 was banned from compounding. Chemically it is the same peptide with a different counter-ion. The marketing implies improved stability and a cleaner legal status; neither claim has independent evidence behind it.
Not approved for human use anywhereNo approval anywhere for human use. Sold under research-use labelling. Not approved. Marketing it as a compliant substitute for a substance FDA excluded from compounding is legally precarious.
| Regulatory status | Not approved. Marketed as a "legal alternative" after BPC-157 was barred from compounding — a claim regulators have not endorsed. |
|---|---|
| Drug class | Arginate salt form of the BPC-157 pentadecapeptide |
| Route | Subcutaneous (research) |
| Half-life | Not established |
| Evidence rating |
1/5 Minimal
Evidence rating 1 out of 5: Minimal
Animal or laboratory data only. No human efficacy evidence. |
| Studied in | No published clinical trials. No independent peer-reviewed characterisation of the salt form versus the acetate form. |
How it works
Identical peptide sequence to BPC-157, formulated as an arginate salt which is claimed to improve stability and absorption. The underlying biological mechanism — if any — is whatever BPC-157 does.
Evidence base
Rated 1 of 5 — Minimal. Animal or laboratory data only. No human efficacy evidence.
- Included on this site because it is heavily marketed, not because evidence supports it.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Possible improved stability Preliminary
Salt selection can genuinely affect peptide shelf stability, though the specific claims for PDA come from vendors rather than published data.
-
Shares BPC-157 preclinical rationale Preliminary
Any preclinical support is inherited from the BPC-157 literature, not generated independently.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Zero independent evidence Serious
There is no published study of PDA as such — not in humans, and not head-to-head against BPC-157 in animals.
-
Regulatory workaround, not a regulatory clearance Serious
Renaming or re-salting a substance barred from compounding does not make it approved. Buyers frequently misread it as legitimised.
-
Inherits every BPC-157 concern Serious
Including the angiogenesis-and-cancer question and the absence of chronic safety data.
-
Unverified product identity Serious
Analytical testing of what is actually in these vials is not routinely available to buyers.
Who should avoid it
- Cancer history or undiagnosed mass
- Pregnancy and breastfeeding
- Tested athletes
If used under medical supervision, monitor
- No validated monitoring exists
Commonly confused with
These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.
Chemically the same peptide with a different counter-ion. PDA is marketed as a lawful alternative to a substance FDA excluded from compounding; that is a commercial framing, not a regulatory clearance.
Compare side by sideRegulatory & legal status
Not approved. Marketing it as a compliant substitute for a substance FDA excluded from compounding is legally precarious.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Pentadeca Arginate (PDA)
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Healing & Tissue Repair
Terms used on this page
- Counterion and Salt Form
- A counterion is the charged partner supplied with a peptide isolated as a salt, and the salt form decides how much of any weighed milligram of powder is actually peptide.
- Primary Structure
- Primary structure is the covalent composition of a peptide, meaning the linear order of its amino acid residues from N-terminus to C-terminus plus any disulfide connectivity and modifications.
- Preclinical Study and Animal Model
- Preclinical studies are the laboratory, cell and animal experiments done before any human exposure, establishing mechanism, target engagement and the toxicology package that permits a first trial.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.